Table S3. Univariate and multivariate analysis of predictive factor for progression-free and LC for MLLs.
| Characteristics | PFS | LC | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate | Multivariate | Univariate | Multivariate | ||||||||
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | ||||
| Histology | – | ||||||||||
| Colorectal | 0.56 (0.19–1.63) | 0.29 | – | – | – | – | – | ||||
| Non-colorectal | – | – | – | – | – | – | – | ||||
| GTV | – | ||||||||||
| <14 mL | 1.19 (0.39–3.65) | 0.75 | – | – | 3.21 (0.64–16.05) | 0.15 | – | ||||
| ≥14 mL | – | – | – | – | – | – | – | ||||
| GTV (continuous) | 1.02 (0.98–1.06) | 0.31 | – | – | 1.07 (1.01–1.13) | 0.01 | 0.98 (0.87–1.10) | 0.75 | |||
| SABR-duration | – | ||||||||||
| <9 days | 1.26 (0.49–3.24) | 0.62 | – | – | 0.74 (0.14–3.83) | 0.72 | – | ||||
| ≥9 days | – | – | – | – | – | – | – | ||||
| SABR-duration (continuous) | 0.99 (0.88–1.11) | 0.91 | – | – | 1.06 (0.88–1.27) | 0.51 | – | – | |||
| Interval to SABR§ | 0.22 | ||||||||||
| <60 days | 2.04 (0.76–5.51) | 0.15 | – | – | 1.01 (0.20–5.12) | 0.98 | – | ||||
| ≥60 days | – | – | – | – | – | – | – | ||||
| Interval to SABR§ (continuous) | 1.00 (0.99–1.02) | 0.26 | – | – | 1.01 (0.99–1.03) | 0.06 | 1.01 (0.99–1.04) | – | |||
| No. of fractions | – | ||||||||||
| <5 fractions | 1.15 (0.45–2.95) | 0.76 | – | – | – | – | – | ||||
| ≥5 fractions | – | – | – | – | – | – | – | ||||
| No. of fractions (continuous) | 1.03 (0.70–2.95) | 0.86 | – | – | 2.15 (1.20–3.85) | 0.01 | 5.2 (0.63–43.70) | 0.12 | |||
| Dose per fraction | 0.22 | ||||||||||
| <12 Gy | 0.42 (0.16–1.08) | 0.07 | 0.05 (0.00–2.28) | 0.12 | 0.14 (0.01–1.25) | 0.07 | 126 (0.05–not reached) | ||||
| ≥12 Gy | – | – | – | – | – | – | – | ||||
| Dose per fraction (continuous) | 0.83 (0.70–1.00) | 0.05 | 1.92 (0.94–3.92) | 0.07 | 0.66 (0.44–0.97) | 0.03 | 0.42 (0.11–1.59) | 0.20 | |||
| Total dose | – | ||||||||||
| <48 Gy | 0.47 (0.10–2.08) | 0.32 | – | – | 1.83 (0.32–10.24) | 0.48 | – | ||||
| ≥48 Gy | – | – | – | – | – | – | – | ||||
| Total dose (continuous) | 0.93 (0.88–0.99) | 0.03 | 0.96 (0.83–1.12) | 0.68 | 1 (0.92–1.09) | 0.96 | – | – | |||
| Prescription IDL | – | ||||||||||
| 80% IDL | 1.86 (0.64–5.40) | 0.25 | – | – | – | – | – | ||||
| 60% IDL | – | – | – | – | – | – | – | ||||
| Treatment technique | – | ||||||||||
| 3D | 2.49 (0.91–6.82) | 0.07 | 10.61 (2.23–50.48) | 0.003 | – | – | – | ||||
| IMRT | – | – | – | – | – | – | – | ||||
| BED10 | – | ||||||||||
| <105 Gy10 | 0.25 (0.05–1.15) | 0.07 | 0.43 (0.02–6.77) | 0.55 | 0.87 (0.14–5.29) | 0.88 | – | ||||
| ≥105 Gy10 | – | – | – | – | – | – | – | ||||
| BED10 (continuous) | 0.97 (0.94–0.99) | 0.02 | 0.97 (0.89–1.06) | 0.61 | 0.98 (0.94–1.01) | 0.29 | – | – | |||
§, interval to SABR was calculated from the first date of diagnosis (biopsy, PET, CT) to the first day of SABR. LC, local control; MLLs, metastatic lung lesions; PFS, progression-free survival; CT, computed tomography; HR, hazard ratio; GTV, gross tumor volume; SABR, stereotactic ablative radiotherapy; IDL, isodose line; 3D, three dimensional; IMRT, intensity-modulated radiation therapy; BED10, biologic effective dose at α/β=10 Gy; PET, positron-emission-tomography; CT, computed tomography.